RxDoctor Payments Data

Alex Hardy, DO

Family Medicine · Valencia, CANPI 1902246580

Payments from drug & device makers

$715in general payments, 2019–2025

Across 43 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$155
  • Boehringer Ingelheim$152
  • Novo Nordisk$127
  • E.r. Squibb & Sons, L.L.C.$79
  • Amgen$69
  • Sobi, Inc$57
  • plus $75 from 4 others

What the payments were for

  • Food & beverage$68596%
  • Education$304%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$715 in reported general payments places this provider in the 65th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$62,696
Medicare patients
164
Services billed
1,507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide131$136,611
EliquisApixaban96$100,026
TrulicityDulaglutide25$37,166
JardianceEmpagliflozin31$36,685
MounjaroTirzepatide34$34,058
XareltoRivaroxaban27$30,890
EntrestoSacubitril/Valsartan20$28,511
JanuviaSitagliptin Phosphate17$20,398
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,981
Tresiba Flextouch U-100Insulin Degludec13$11,120
Spiriva RespimatTiotropium Bromide20$10,497
Atorvastatin Calcium703$9,022
Breo ElliptaFluticasone/Vilanterol16$6,559
PentasaMesalamine12$6,384
Diltiazem 12hr ErDiltiazem Hcl16$6,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$127$136,611131 claims
PfizerEliquis$155$100,02696 claims
Boehringer IngelheimJardiance, Spiriva Respimat$152$47,18151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 10,533 family medicine providers in California.

Other family medicine in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →